Get the Stockscreener App
12.96
3.43%
-0.46
Pre-market:
13.01
0.05
+0.39%
Evolus Inc stock is traded at $12.96, with a volume of 531.65K.
It is down -3.43% in the last 24 hours and down -13.83% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$13.42
Open:
$13.27
24h Volume:
531.65K
Relative Volume:
0.73
Market Cap:
$824.08M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-12.00
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
-4.00%
1M Performance:
-13.83%
6M Performance:
-25.90%
1Y Performance:
-7.69%
1-Day Range:
$12.71
$13.41
1-Week Range:
$11.93
$13.81
52-Week Range:
$9.25
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
12.96 | 824.08M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
160.06 | 71.67B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 47.44B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.19 | 46.08B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.46 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.36 | 13.97B | 612.78M | -86.37M | -62.91M | -0.87 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus’s SWOT analysis: fda approval boosts stock as dermal filler market expands By Investing.com - Investing.com South Africa
Evolus’s SWOT analysis: fda approval boosts stock as dermal filler market expands - Investing.com India
Evolus at Barclays Conference: Strategic Growth and New Launch - Investing.com
Evolus at Leerink’s Global Healthcare Conference: Strategic Growth Insights - Investing.com India
Evolus at Leerink’s Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas - The Motley Fool
What is HC Wainwright’s Estimate for Evolus FY2025 Earnings? - Defense World
(EOLS) Investment Analysis - Stock Traders Daily
Evolus, Inc.: Navigating Financial Challenges Amidst Ongoing Losses and Market Uncertainty - MSN
Global Jeuveau Market Outlook 2025-2034: Growth Drivers, Share, And Trends - EIN News
Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Principal Financial Group Inc. - Defense World
Evolus, Inc. to Host Earnings Call - ACCESS Newswire
Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Rhumbline Advisers - Defense World
IFP Advisors Inc Has $52,000 Position in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus’s Strong Market Position and Growth Potential Highlighted by Robust Revenues and Strategic Expansions - TipRanks
HC Wainwright Reaffirms “Buy” Rating for Evolus (NASDAQ:EOLS) - Defense World
Evolus’s Promising Growth and Strategic Positioning Earns a ‘Buy’ Rating from Analyst Douglas Tsao - TipRanks
Evolus, Inc. Earnings Call Highlights Robust Growth and Profitability - TipRanks
Evolus Inc Reports Q4 2024 Revenue of $79 Million, Surpassing Es - GuruFocus.com
Stifel maintains Buy on Evolus stock, sets $25 target By Investing.com - Investing.com UK
H.C. Wainwright maintains Buy rating on Evolus stock at $27 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Evolus stock at $27 target - Investing.com
Evolus Celebrates Strong Demand For Jeuveau Wrinkle Treatment - Finimize
Assessing Evolus: Insights From 6 Financial Analysts - Benzinga
Evolus price target raised to $25 from $22 at Barclays - TipRanks
Evolus reports Q4 EPS (11c) vs (21c) last year - TipRanks
Evolus, Inc. (NASDAQ:EOLS) Q4 2024 Earnings Call Transcript - Insider Monkey
Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - Yahoo Finance
Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... By GuruFocus - Investing.com Canada
Evolus, Inc. Achieves Record Financial Growth in 2024 - TipRanks
Evolus Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Evolus earnings missed by $0.13, revenue topped estimates - Investing.com Canada
EVOLUS Earnings Results: $EOLS Reports Quarterly Earnings - Nasdaq
Evolus Q4 Net Loss Narrows, Revenue Rises; Issues Guidance -March 04, 2025 at 05:42 pm EST - Marketscreener.com
Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates - Yahoo Finance
Evolus stock rises as Q4 revenue beats estimates, 2025 outlook strong - Investing.com Australia
Evolus stock rises as Q4 revenue beats estimates, 2025 outlook strong By Investing.com - Investing.com South Africa
Evolus, Inc. SEC 10-K Report - TradingView
Earnings Flash (EOLS) EVOLUS Reports Q4 Revenue $78.9M, vs. FactSet Est of $79M - Marketscreener.com
Evolus posts quarterly profit on strong sales of cosmetic injection -March 04, 2025 at 04:05 pm EST - Marketscreener.com
Evolus posts quarterly profit on strong sales of cosmetic injection - TradingView
Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now? - MSN
EVOLUS Earnings Preview: Recent $EOLS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Evolus (EOLS) to Release Earnings on Tuesday - Defense World
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences - Business Wire
How To Trade (EOLS) - Stock Traders Daily
Evolus Management to Reveal Strategic Insights at Two Major Healthcare Investor Conferences - StockTitan
Rice Hall James & Associates LLC Acquires 43,381 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit - BioSpace
Inside Evolus's Growth Strategy: CEO Takes Center Stage at Elite Beauty Summit - StockTitan
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 - BioSpace
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):